| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
MBP-reactive LV-4 T cell lines' antigen-specific proliferation is inhibited by luteindole (N-0774) (5–10 μg/ml) [1].
|
|---|---|
| ln Vivo |
Experimental autoimmune encephalomyelitis is inhibited by luzindole (N-0774) (30 mg/kg; i.p.; days 0-5) [2]. In a dose-dependent manner, luzindole (N-0774) (30 mg/kg ip) shortens immobility time; the impact is greater at midnight (60% decrease) than it is at midday (39% reduction). Luzindole's effects are time-dependent, peaking after 60 minutes. The anti-immobility effects of luzidole (10 mg/kg ip) are countered by the administration of melatonin (30 mg/kg ip). Luzindole (30 mg/kg ip) does not change albino ND/4 mice's or C57BL/6J mice's non-melatonin-producing immobility time at midday or midnight [3].
|
| Animal Protocol |
Animal/Disease Models: 23 to 12 weeks old (SJL , under minimal lighting conditions)
Experimental Results: Effective prevention of experimental autoimmune encephalomyelitis. |
| References |
|
| Additional Infomation |
Luzindole is a member of the class of indoles that is tryptamine in which one of the amino hydrogens is replaced by an acetyl group while the hydrogen at position 2 is replaced by a benzyl group. It has a role as a melatonin receptor antagonist. It is a member of acetamides and a member of indoles. It is functionally related to a tryptamine.
|
| Molecular Formula |
C19H20N2O
|
|---|---|
| Molecular Weight |
292.3749
|
| Exact Mass |
292.157
|
| Elemental Analysis |
C, 78.05; H, 6.90; N, 9.58; O, 5.47
|
| CAS # |
117946-91-5
|
| Related CAS # |
Luzindole HCl;117946-91-5;
|
| PubChem CID |
122162
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
559.6±38.0 °C at 760 mmHg
|
| Melting Point |
44-46°C
|
| Flash Point |
292.2±26.8 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
3.04
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
364
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C([H])([H])[H])N([H])C([H])([H])C([H])([H])C1C2=C([H])C([H])=C([H])C([H])=C2N([H])C=1C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
WVVXBPKOIZGVNS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H20N2O/c1-14(22)20-12-11-17-16-9-5-6-10-18(16)21-19(17)13-15-7-3-2-4-8-15/h2-10,21H,11-13H2,1H3,(H,20,22)
|
| Chemical Name |
N-[2-(2-benzyl-1H-indol-3-yl)ethyl]acetamide
|
| Synonyms |
Luzindole, N-0774, N0774, N 0774, N-acetyl-2-benzyltryptamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~342.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4203 mL | 17.1016 mL | 34.2032 mL | |
| 5 mM | 0.6841 mL | 3.4203 mL | 6.8406 mL | |
| 10 mM | 0.3420 mL | 1.7102 mL | 3.4203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
